Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Marijuana Abuse 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Oxaliplatin 13Bevacizumab 11Capecitabine 10Fluorouracil 8Blood Specimen Collection 8Leucovorin 7Cetuximab 6pembrolizumab 5Folfox protocol 5trifluridine tipiracil drug combination 4dostarlimab 4Nivolumab 4Irinotecan 4HMPL-013 4Drug Therapy 4fludarabine 3XELOX 3Specimen Handling 3Laparoscopy 3IFL protocol 3Cyclophosphamide 3Biopsy 3tislelizumab 2tipiracil 2regorafenib 2pertuzumab 2envafolimab 2encorafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Colonic Neoplasms × Cannabidiol × Clear all
NCT06731894 2025-12-05

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

City of Hope Medical Center

Phase 2 Recruiting
120 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡